{"Symbol": "ARGX", "AssetType": "Common Stock", "Name": "argenx NV ADR", "Description": "argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.", "CIK": "1697862", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "LAARDERHOOGTWEG 25, AMSTERDAM, NETHERLANDS, 1101 EB", "OfficialSite": "https://argenx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "50865689000", "EBITDA": "721409000", "PERatio": "35.11", "PEGRatio": "0.901", "BookValue": "99.66", "DividendPerShare": "None", "DividendYield": "None", "EPS": "23.41", "RevenuePerShareTTM": "2.416", "ProfitMargin": "0.416", "OperatingMarginTTM": "0.304", "ReturnOnAssetsTTM": "0.0483", "ReturnOnEquityTTM": "0.247", "RevenueTTM": "3683281000", "GrossProfitTTM": "2020001000", "DilutedEPSTTM": "23.41", "QuarterlyEarningsGrowthYOY": "2.727", "QuarterlyRevenueGrowthYOY": "0.955", "AnalystTargetPrice": "1034.97", "AnalystRatingStrongBuy": "5", "AnalystRatingBuy": "15", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "1", "TrailingPE": "35.11", "ForwardPE": "27.7", "PriceToSalesRatioTTM": "13.81", "PriceToBookRatio": "8.34", "EVToRevenue": "13.35", "EVToEBITDA": "49.88", "Beta": "-0.173", "52WeekHigh": "934.62", "52WeekLow": "510.06", "50DayMovingAverage": "841.1", "200DayMovingAverage": "729.59", "SharesOutstanding": "61883000", "SharesFloat": "61145000", "PercentInsiders": "0.005", "PercentInstitutions": "52.051", "DividendDate": "None", "ExDividendDate": "None"}